NIH/ Vaccines against Pathogens with Small Market Yes Yes No NIAID 039 Potential NIH/ Development of Primer and Reference Tool to Yes No No NIDA 158 Assess Neonatal Abstinence Syndrome NIH/ Therapeutic Cannabidiol Pulmonary Delivery Device Yes No No NIDA 159 (e.g. Nebulizer, Vaporizer, or Inhaler) NIH/ Remote Pain Management “The Pain Mobile:” Yes No No NIDA 160 System CDC/ Diagnostic Tools to Support the Elimination and Yes No No CGH 008 Control of Neglected Tropical Diseases CDC/ De novo assembly of arthropod genomes of public Yes No No NCEZID 012 health importance CDC/ Detecting Lower Intestinal Microbiome Disruption Yes No No NCEZID 013 and Multidrug Resistant Organisms CDC/ Serologic measurement of hepatitis B virus cccDNA Yes No No NCHHSTP 046 CDC/ Serologic detection and quantification of hepatitis B Yes No No NCHHSTP 047 core antigen CDC/ Transcutaneous immunization against rotavirus using Yes No No NCIRD 031 a dissolvable microneedle patch CDC/ Thermostable Dry Powder Live Attenuated Influenza Yes No No NCIRD 032 Vaccine for Nasal Delivery All firms that are awarded Phase I contracts originating from this solicitation will be eligible to participate in Phases II and III. HHS Components will notify Phase I awardees of the Phase II proposal submission requirements. Submission of Phase II proposals will be in accordance with dates provided by individual Component instructions. The details on the due date, content, and submission requirements of the Phase II proposal will be provided by the awarding HHS Component either in the Phase I award or by subsequent notification. The HHS is not obligated to make any awards under Phase I, Phase II, or Phase III, and all awards are subject to the availability of funds. HHS is not responsible for any monies expended by the offeror before award of any contract.
NIH/ NIAID 039 Yes Yes No Vaccines against Pathogens with Small Market Potential NIH/ NIDA 158 Yes No No Development of Primer and Reference Tool to Assess Neonatal Abstinence Syndrome NIH/ NIDA 159 Yes No No Therapeutic Cannabidiol Pulmonary Delivery Device (e.g. Nebulizer, Vaporizer, or Inhaler) NIH/ NIDA 160 Yes No No “The Pain Mobile:” Remote Pain Management System CDC/ CGH 008 Yes No No Diagnostic Tools to Support the Elimination and Control of Neglected Tropical Diseases CDC/ NCEZID 012 Yes No No De novo assembly of arthropod genomes of public health importance CDC/ NCEZID 013 Yes No No Detecting Lower Intestinal Microbiome Disruption and Multidrug Resistant Organisms CDC/ NCHHSTP 046 Yes No No Serologic measurement of hepatitis B virus cccDNA CDC/ NCHHSTP 047 Yes No No Serologic detection and quantification of hepatitis B core antigen CDC/ NCIRD 031 Yes No No Transcutaneous immunization against rotavirus using a dissolvable microneedle patch CDC/ NCIRD 032 Yes No No Thermostable Dry Powder Live Attenuated Influenza Vaccine for Nasal Delivery All firms that are awarded Phase I contracts originating from this solicitation will be eligible to participate in Phases II and III. HHS Components will notify Phase I awardees of the Phase II proposal submission requirements. Submission of Phase II proposals will be in accordance with dates provided by individual Component instructions. The details on the due date, content, and submission requirements of the Phase II proposal will be provided by the awarding HHS Component either in the Phase I award or by subsequent notification. The HHS is not obligated to make any awards under Phase I, Phase II, or Phase III, and all awards are subject to the availability of funds. HHS is not responsible for any monies expended by the offeror before award of any contract.
PHS2016-1.docx